(Q51748822)
Statements
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial (English)
Michael Roden
Jianping Weng
Jens Eilbracht
Gabriel Kim
Hans J Woerle
Uli C Broedl
EMPA-REG MONO trial investigators
9 September 2013